• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Carolyn N. Krasner, M.D.


  • Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS.Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.Int J Gynecol Cancer. 2013 Sep;23(7):1219-25.
  • del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S.Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.Med Oncol. 2013 Mar;30(1):435.
  • Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM.Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis.Eur J Cancer. 2012 Oct;48(15):2361-8.
  • Krasner CN, Poveda A, Herzog TJ, Vermorken JB, Kaye SB, Nieto A, Claret PL, Park YC, Parekh T, Monk BJ.Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.Gynecol Oncol. 2012 Oct;127(1):161-7.
  • Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN.Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.Int J Clin Oncol. 2010 Aug;15(4):390-8.
  • Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM.Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer.J Clin Oncol. 2010 Jul 1;28(19):3107-14.
  • Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT.Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.Gynecol Oncol. 2010 Feb;116(2):168-72.
  • Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM.Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.J Clin Oncol. 2010 Jan 1;28(1):154-9.
  • Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT.Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.J Clin Oncol. 2009 Nov 20;27(33):5601-6.
  • Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN.A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.Gynecol Oncol. 2009 Dec;115(3):443-6.
  • Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT.Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.J Allergy Clin Immunol. 2009 Jun;123(6):1262-7.e1.
  • Miller DS,Blessing JA,Krasner CN,Mannel RS,Hanjani P,Pearl ML,Waggoner SE,Boardman CH.Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.J Clin Oncol. 2009 Jun 1;27(16):2686-91.
  • Matulonis UA,Krag KJ,Krasner CN,Atkinson T,Horowitz NS,Lee H,Penson RT.Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors.Gynecol Oncol. 2009 Feb;112(2):394-9.
  • Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT.Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.J Clin Oncol. 2008 Dec 10;26(35):5761-6.
  • Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E.Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.N Engl J Med. 2006 Apr 13;354(15):1615-25.